on behalf of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators
D ecreased renal function has consistently been found to be an independent risk factor for cardiovascular (CV) disease outcomes and all-cause mortality in a large spectrum of CV patients, including those with left ventricular systolic dysfunction and chronic heart failure (CHF). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] In terms of clinical application, renal function may potentially be a stronger predictor of clinical events than left ventricular ejection fraction (LVEF). 3 However, most studies in CHF have been conducted in patients with markedly reduced LVEF, and data in patients with more preserved LV systolic function are scarce. In addition, specific data on the prognostic value of renal function in patients who are intolerant to ACE inhibitors are lacking: Given the known interactions between treatment with an ACE inhibitor and renal function, these patients are of particular interest. Because the latter two groups form a significant proportion of the CHF population, it would be important to specifically collect and analyze data in these patients.
The Candesartan in Heart Failure:Assessment of Reduction in Mortality and Morbidity (CHARM)-Overall program was an assessment of candesartan in three distinct CHF populations; LVEF higher than 40% (CHARM-Preserved), 40% or lower and treated with an ACE inhibitor (CHARM-Added), or 40% or lower and not treated with an ACE inhibitor because of previous intolerance (CHARM-Alternative). These trials provide a unique opportunity to study prognostic properties of renal function and the interplay with renin-angiotensin-aldosterone system inhibitor therapy in a broad spectrum of patients with CHF. [13] [14] [15] [16] The first aim of the present analysis was to examine the prevalence of decreased renal function in the three CHARM groups and to study whether decreased renal function is as common in patients with preserved as it is in those with impaired LV systolic function. Second, we investigated the prognostic value of renal function on CV mortality and morbidity outcomes, adjusted for traditional prognostic markers, with special attention to LVEF and treatment allocation.
Methods
The rationale and details of the CHARM program have been described previously. 13 Eligible patients were women and men aged 18 years or older who had symptomatic heart failure (New York Heart Association class II-IV) for at least 4 weeks' duration. Major exclusion criteria included serum creatinine 3 mg/dL (265 mol/L) or more, serum potassium 5.5 mmol/L (mEq/L) or more, known bilateral renal artery stenosis, symptomatic hypotension, critical aortic or mitral stenosis, recent (within 4 weeks) myocardial infarction, stroke, or open heart surgery and use of an angiotensin receptor blocker in the previous 2 weeks. Eligible consented patients were enrolled into one of three trials, done concurrently, according to LVEF higher than 40% (CHARM-Preserved, nϭ3023), 40% or lower and treated with an ACE inhibitor (CHARM-Added, nϭ2048), or 40% or lower and not treated with an ACE inhibitor because of previous intolerance (CHARM-Alternative, nϭ2028). 14 -16 The present patient cohort was derived from the 2743 patients enrolled in North America, where baseline serum creatinine assessments were done as part of the screening process to determine eligibility, using a central laboratory. The primary outcome for each of the three component trials was CV death or unplanned admission to hospital for the management of worsening CHF and all-cause death for the overall program (nϭ7599), which were also used as the outcome measures in this supplementary analysis.
Renal Function
An estimated glomerular filtration rate (eGFR) at baseline was calculated in 2680 patients with sufficient data, with the use of the modified Modification of Diet in Renal Disease (MDRD) fourcomponent equation incorporating age, race, gender, and serum creatinine level, which has been used in several large clinical trials. 9, [17] [18] [19] This "simplified" MDRD formula (mL/min per 1.73m 2 ) is calculated according to the following equation for male subjects: 186.3ϫ(serum creatinine) Ϫ1.154 ϫ(age) Ϫ0.203 . The product of this equation was multiplied by a correction factor for female subjectsϫ0.742, for black male subjectsϫ1.212, and for black female sub-jectsϫ1.212ϫ0.742. The eGFR was categorized into approximate quintiles using sensible cutoffs for the ease of interpretation close to cutoff points as specified by the National Kidney Disease Foundation Outcomes Quality Initiative (NKF-K/DOQI) Guidelines. 20
Statistical Methods
Associations between baseline variables were assessed through the use of 1-way ANOVA, the Kruskal-Wallis test, and 2 or Fisher exact tests, when appropriate. Two-sided P values were used, taking PϽ0.05 to be significant. Both major outcomes (CV death or unplanned heart failure hospitalization; all-cause mortality) were analyzed as time to first event for this cohort of 2680 CHARM patients over the duration of the 4-year program (median follow-up, 34.4 months). Continuous variables were categorized for graphical investigation of the proportionality of hazards and estimation of crude stratum-specific rates. We used a Cox proportional hazards model to estimate hazard ratios with 95% CI. Multivariate adjustment was performed on characteristics selected a priori, including antihypertensive medications, which might confound the association of renal function with the risk of both major outcomes. Nonlinear terms were entered into the model to assess effects at the tail of the distribution, when supported by the statistical model. Inspection of the martingale residuals suggested a quadratic transformation for the continuous variable eGFR. Hence, eGFR (centered on 75 mL/min per 1.73 m 2 ) was entered either as a continuous variable (assuming a nonlinear effect) or as categorical variable. Age (above 60 years), heart rate, and diastolic blood pressure were entered as continuous linear variables. Age (60 years or below), the presence of ischemic CHF, diabetes, smoking, atrial fibrillation, angina, prior stroke or myocardial infarction, prior hospitalizations for CHF, LVEF, smoking status, and severity of clinical symptoms as assessed by NYHA functional class were entered as categoric variables. We also evaluated the effect of random assignment to candesartan. The final multivariable model with the use of exact quintiles of eGFR and LVEF was used to estimate quintile-specific hazard ratios and derive adjusted relative risk estimates. Finally, the robustness of the primary analysis was tested in a secondary analysis by using serum creatinine. The purpose of the latter analysis was to investigate whether the observed differences in results would hold if serum creatinine was used instead of eGFR, a more conservative scenario. All analyses were performed with Stata 8. 
Results
A baseline serum creatinine measurement was missing in 61 of the 2743 patients. In 2 patients, the serum creatinine concentration recorded was Ͼ10 mg/dL, and these patients were excluded from the analysis. In the cohort of 2680 patients included in this analysis, 1087 were enrolled from CHARM-Preserved, 931 from CHARM-Added, and 662 from CHARM-Alternative. This North American cohort had a higher body mass index and a higher rate of hypertension, CV disease, diabetes, worse clinical heart failure, and ex-smokers when compared with the other regions.
Estimated GFR and Its Association With Other Baseline Characteristics
In Table 1 , baseline characteristics are shown across quintiles of eGFR at baseline. The number of comorbidities at baseline increased with decreasing eGFRs. Patients in the lowest category of eGFR had the highest rates of prior diabetes, myocardial infarction, stroke, hospitalizations for CHF, atrial fibrillation, and angina pectoris. Lower eGFR was associated with less current smokers and more treatment with diuretics, spironolactone, and vasodilators. Patients with lower eGFR were less likely to be treated with a ␤-blocker. There was no relation between eGFR and ACE inhibitor use, and there was no evidence for an association between LVEF and eGFR (Pϭ0.5), although a greater proportion of patients with a low eGFR had a worse NYHA class. Figure 1 shows the cumulative distribution of eGFR in CHARM-Preserved, CHARM-Added, and CHARM-Alternative. The mean eGFR in CHARM-Alternative was slightly lower than in CHARM-Added and CHARM-Preserved. The estimated mean difference in eGFR between CHARM-Added and CHARM-Alternative was 5.2 (95% CI, 2.54 to 7.87; PϽ0.001) and between CHARM-Preserved and CHARM-Alternative was 4.42 mL/min per 1.73 m 2 (95% CI, 1.83 to 7.00; Pϭ0.001), respectively. Similar findings were observed when calculating cumulative distributions of serum creatinine. The proportion of patients with eGFR Ͻ60 mL/min per 1.73 m 2 was 36.0%; 42.6% for CHARM-Alternative, 33.0% for CHARM-Added, and 34.7% for CHARM-Preserved.
Estimated GFR at Baseline and Clinical Outcome
After a median follow-up of 34.4 months (range, 1 day to 45.2 months) and observation time of 6493 person-years, 950 of 2680 patients had CV death or admission to the hospital for heart failure in the time-to-event analysis, and there were 625 deaths (all-cause mortality). Figure 2 shows that there was a stepwise increase in the cumulative incidence of CV death or admission to hospital for heart failure across successively lower quintiles of eGFR. There was a less clear separation between the curves for the higher eGFR quintiles, and the most marked differences were observed for an eGFR below 60 mL/min per 1.73 m 2 . Similar patterns were observed between eGFR divided into Ͻ45.0, 45.0 to 60.0, and Ͼ60 mL/min per 1.73 m 2 and cardiovascular death or admission to hospital for heart failure stratified for preserved LVEF (Figure 3 ). 
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The results of multivariate modeling are displayed in Tables 2 and 3 and in Figure 4 . Both a reduced eGFR and lower LVEF were found to be significant independent predictors of worse outcome after adjustment for major confounding baseline clinical characteristics. The effects of eGFR remained significant in both multivariable models (PϽ0.001). When using eGFR as a continuous variable, there was a nonlinear relation between eGFR, both in crude and adjusted analyses (Wald test for quadratic term, Pϭ0.001 for both outcomes). This nonlinear effect was particularly present within the lowest eGFR quintile. Finally, the prognostic value of eGFR was compared between the three component trials, and there was no difference; that is, there was no evidence for an interaction for either outcome. There was also no interaction between eGFR and LVEF (Wald test for interaction term, Pϭ0.42) or interaction between the treatment effect of candesartan and eGFR (Wald test for interaction term, Pϭ0.88).
In a secondary analysis with creatinine, both increased creatinine and lower LVEF were found to be significant independent predictors of worse outcome after adjustment for major confounding baseline clinical characteristics (data not shown). In both multivariable models, there was no substantial evidence for a nonlinear effect of creatinine (Wald tests for the quadratic terms, Pϭ0.09 for the primary outcome, Pϭ0.36 for the secondary outcome). Finally, there was no evidence for an interaction between creatinine and LVEF (Wald test for interaction term, Pϭ0.57) or for an interaction between creatinine and the effect of candesartan (Wald test for interaction term, Pϭ0.84), gender, diabetes, or age.
Discussion
The main finding of the present analysis from the CHARM program is that renal function, as reflected by eGFR through the use of the simplified MDRD formula, is strongly associated with prognosis in a broad spectrum of patients with CHF. This risk from renal insufficiency persists even after adjustment for all other known covariates, including LVEF. Moreover, no evidence for interaction was observed among renal function, treatment allocation, and primary outcome.
Renal insufficiency, as reflected by a GFR of less than 60.0 mL/min per 1.73 m 2 of body surface area, is relatively common in patients with CHF. Evidence is accumulating that renal impairment may also independently contribute to an increased CV morbidity and mortality risk in patients with CHF; this applies to patients with systolic as well as those with diastolic dysfunction. 2,3,5,6,12 The interpretation of this finding is that the presence of renal dysfunction in itself remains an important independent risk factor for CV death or heart failure hospitalization.
Our study differs from previous reports, as the CHARM program included a broad spectrum of patients with CHF with respect to both LVEF as well as use of ACE inhibitors. Within this context, it is noteworthy that although cumulative distributions of estimated renal function were slightly different in CHARM-Preserved and CHARM-Added when compared with CHARM-Alternative, the prognostic value of renal function was comparable in these CHF patient populations.
Several explanations have been proposed for the observed prognostic value of renal function in CHF. First, renal function can be seen as direct reflection of an impaired hemodynamic status that is related to the severity of the underlying (ie, cardiac) disease. 21, 22 In the present study, we did not measure invasive hemodynamics. We found no interaction between eGFR and LVEF, indicating that eGFR and cardiac function had effects that were independent in terms of predicting the primary end point. Second, renal dysfunction might be a marker of general vascular disease and therefore possibly reflects severity of atherosclerosis in both kidney and heart. 23, 24 Although our study cannot resolve this debate, the strong independent effect of renal function in our analysis after adjustment for numerous cardiac risk factors shows that renal function is a valuable predictive variable in evaluating outcomes, even if it probably represents partly underlying atherosclerotic or hypertensive vascular disease.
An interesting finding in the present study is the lower eGFR in CHARM-Alternative, when compared with CHARM-Added or CHARM-Preserved. This could be due to selection because a frequent reason for not using ACE inhibitors in patients with heart failure is the concern for complications attributable to worsened renal function, especially in the situation of renal insufficiency. In a post hoc analysis of Studies of Left Ventricular Dysfunction (SOLVD), initiating treatment with enalapril increased the risk of diuretic-associated renal impairment in patients with CHF. 25 However, in CHARM-Alternative, the most common reason for ACE inhibitor intolerance was cough (72%), and renal dysfunction was the reason in only 12% of the cases. It could be speculated that the lower eGFR in CHARM-Alternative might be related to the absence of the renopro- tective effects of ACE inhibition in the past. Supportive evidence is coming from experimental models and other clinical conditions. 26 Therapies directed at inhibiting AII formation and at binding to the AT 1 receptor have been shown to reduce end-organ damage in the kidneys in diabetics and hypertensives. [27] [28] [29] [30] [31] In CHARM-Preserved, however, only a minority of patients were taking an ACE inhibitor, so these differences in eGFR between trials probably are multifactorial and not primarily attributable to the background use of an ACE inhibitor.
In CHARM, a strong association between impaired renal function and insulin-dependent diabetes was observed, whereas the prevalence of non-insulin-dependent diabetes mellitus was equally distributed over the different ranges of renal function. This might be explained by the fact that the latter form of diabetes is at an earlier stage of progression, with fewer manifestations of microvascular and macrovascular disease complications.
One of the potential limitations of this study is that there may be unmeasured confounders that could have influenced our results. Although the observed relations between renal function and CV prognosis remained statistically significant after correction for classic risk factors, we did not account for the more recently reported confounding risk factors such as lipoproteins and hyperhomocysteinemia. 32, 33 Also, renal function was estimated by the simplified MDRD equation, that is, an indirect, creatinine-based assessment of renal function. This and other equations were mainly validated in populations with moderately to severely impaired renal function. In view of the overall findings being consistent irrespective of the algebraic transformation of creatinine with and without adjustments for gender, age, and other risk factors, we believe that our results are relatively robust. However, it is not possible to extrapolate these findings to patients with more severe renal dysfunction because the trial excluded patients with baseline serum creatinine values Ն265 mol/L (Ն3 mg/dL).
Conclusions
We have shown that in a broad spectrum of patients with CHF, including those with reduced as well as preserved left ventricular systolic function and including those either receiving an ACE inhibitor or not receiving an ACE inhibitor due to intolerance, renal function, as reflected by eGFR using *Categories referring to mean LVEF within that category. †Covariates used for adjustment: allocated treatment, smoking, gender, ethnicity, age, heart rate, systolic blood pressure, diastolic blood pressure, NYHA class, medical history (diabetes, prior angina, prior stroke or myocardial infarction, prior hospitalizations for CHF), and medication (ACE inhibitors, diuretics, ␤-blockers, calcium channel blockers, spironolactone, other vasodilators, aspirin). the simplified MDRD formula, is strongly and independently associated with prognosis. Taking into account the renal exclusion criteria of CHARM (serum creatinine Ն3 mg/dL (Ն 265 mol/L), the clinical effectiveness of candesartan was evident irrespective of underlying renal function, as no statistical interaction was observed between renal function, treatment allocation, and clinical outcome. 
